The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination

Proceedings of the Royal Society B: Biological Sciences

Volumn 280, Issue 1771, 2013, Pages

  Flasche, Stefan ^a,b,c   John Edmunds, W ^a,c   Miller, Elizabeth ^a   Goldblatt, David ^d   Robertson, Chris ^b,e,f   Choi, Yoon Hong ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HEALTH PROTECTION SCOTLAND   (United Kingdom)

^f INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Carriage; Coexistence; Competition; Immunity; Streptococcus pneumoniae; Vaccination

Indexed keywords

BACTERIUM; COEXISTENCE; COMPETITION (ECOLOGY); FITNESS; HOST-PATHOGEN INTERACTION; IMMUNITY; NUMERICAL MODEL; VACCINATION;

AGE; BIOLOGICAL MODEL; CLASSIFICATION; COMPUTER SIMULATION; HUMAN; IMMUNOLOGY; MICROBIOLOGY; NASOPHARYNX; ORGANISMAL INTERACTION; PATHOGENICITY; PNEUMOCOCCAL INFECTION; PROCEDURES; SPECIES DIFFERENCE; STREPTOCOCCUS PNEUMONIAE; TRANSMISSION; UNITED KINGDOM; VACCINATION;

AGE FACTORS; CLASSIFICATION; COMPUTER SIMULATION; GREAT BRITAIN; HUMANS; IMMUNOLOGY; METHODS; MICROBIAL INTERACTIONS; MICROBIOLOGY; MODELS, BIOLOGICAL; NASOPHARYNX; PATHOGENICITY; PNEUMOCOCCAL INFECTIONS; SPECIES SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; TRANSMISSION; VACCINATION;

EID: 84902654115     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2013.1939     Document Type: Article

References (55)

1. O'Brien KL et al. 2009 Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 903-911. (doi:10.1016/S0140-6736(09)61203-4)
2. WHO. 2011 Estimated Hib and pneumococcal deaths for children under 5 years of age. See http://www. who.int/immunization_monitoring/burden/ Pneumo_hib_estimates/en/index2.html.
3. Weinberger DM, Malley R, Lipsitch M. 2011 Serotype replacement in disease after pneumococcal vaccination. Lancet 6736, 1-12. (doi:10.1016/ S0140-6736(10)62225-8)
4. Weinberger DM et al. 2009 Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathogens 5, e1000476. (doi:10. 1371/journal.ppat.1000476)
5. Black S et al. 2000 Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187-195. (doi:10.1097/ 00006454-200003000-00003)
6. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N, Yagupsky P. 1996 Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174, 1271-1278. (doi:10.1093/infdis/174.6.1271)
7. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P, Fraser D. 2002 Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185, 927-936. (doi:10.1086/339525)
8. Flasche S, Hoek AJV, Sheasby E, Waight P, Andrews N, George R, Miller E, van Hoek AJJ, Sheppard C. 2011 Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med. 8, e1001017. (doi:10.1371/journal.pmed.1001017)
9. Huang SS et al. 2009 Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 124, e1-e11. (doi:10.1542/peds.2008-3099)
10. Vestrheim DF, Høiby EA, Aaberge IS, Caugant DA. 2010 Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin. Vaccine Immunol? 17, 325-334. (doi:10.1128/CVI.00435-09)
11. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. 2011 Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 11, 760-768. (doi:10.1016/S1473-3099(11)70090-1)
12. Pilishvili T et al. 2010 Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201, 32-41. (doi:10.1086/648593)
13. Wals PD, Robin E, Fortin E, Thibeault R, Ouakki M, Douville-Fradet M. 2008 Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 27, 963-968. (doi:10.1097/ INF.0b013e31817cf76f)
14. Rodenburg GD, de Greeff SC, Jansen AGCS, de Melker HE, Schouls LM, Hak E, Spanjaard L, Sanders EAM, van der Ende A. 2010 Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg. Infect. Dis. 16, 816-823. (doi:10.3201/eid1605.091223)
15. Lipsitch M. 1997 Vaccination against colonizing bacteria with multiple serotypes. Proc. Natl Acad. Sci. USA 94, 6571-6576. (doi:10.1073/pnas.94.12.6571)
16. Salisbury D. 2010 Introduction of Prevenar 13 into the Childhood Immunisation Programme. 1-8. See http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/documents/digitalasset/ dh_112192.pdf.
17. GAVI. 2013 Pneumococcal vaccine support. See http://www.gavialliance.org/support/nvs/ pneumococcal/.
18. Melegaro A, Choi YH, George R, Edmunds WJ, Miller E, Gay NJ. 2010 Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease. BMC Infect. Dis. 10, 90. (doi:10.1186/1471-2334-10-90)
19. Lipsitch M, Colijn C, Cohen T, Hanage WP, Fraser C. 2009 No coexistence for free: neutral null models for multistrain pathogens. Epidemics 1, 2-3. (doi:10.1016/j.epidem.2008.07.001)
20. Colijn C, Cohen T, Fraser C, Hanage W, Goldstein E, Givon-Lavi N, Dagan R, Lipsitch M. 2010 What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae? J. R. Soc. Interface 7, 905-919. (doi:10.1098/rsif.2009.0400)
21. Cobey S, Lipsitch M. 2012 Niche and neutral effects of acquired immunity permit coexistence of pneumococcal serotypes. Science 335, 1376-1380. (doi:10.1126/science.1215947)
22. Weinberger DM, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. 2008 Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. J. Infect. Dis. 197, 1511-1518. (doi:10.1086/587941)
23. Granat SM, Ollgren J, Herva E, Mia Z, Auranen K, Mäkelä PH. 2009 Epidemiological evidence for serotype-independent acquired immunity to pneumococcal carriage. J. Infect. Dis. 200, 99-106. (doi:10.1086/599364)
24. Goldblatt D et al. 2005 Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J. Infect. Dis. 192, 387-393. (doi:10.1086/431524)
25. Hill PC, Cheung YB, Akisanya A, Sankareh K, Lahai G, Greenwood BM, Adegbola RA. 2008 Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin. Infect. Dis. 46, 807-814. (doi:10.1086/ 528688)
26. Zhang Y, Auranen K, Eichner M. 2004 The influence of competition and vaccination on the coexistence of two pneumococcal serotypes. Epidemiol. Infect. 132, 1073-1081. (doi:10.1017/S095026880 4002894)
27. Auranen K, Mehtälä J, Tanskanen AS, Kaltoft M, Mehtala J, Kaltoft MS, Mehtala J. 2010 Betweenstrain competition in acquisition and clearance of pneumococcal carriage: epidemiologic evidence from a longitudinal study of day-care children. Am. J. Epidemiol. 171, 169-176. (doi:10.1093/aje/ kwp351)
28. Choi YH, Jit M, Flasche S, Gay N, Miller E. 2012 Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PLoS ONE 7, e39927. (doi:10.1371/journal.pone.0039927)
29. Melegaro A, Choi Y, Pebody R, Gay N. 2007 Pneumococcal carriage in United Kingdom families: estimating serotype-specific transmission parameters from longitudinal data. Am. J. Epidemiol. 166, 228-235. (doi:10.1093/ aje/kwm076)
30. Melegaro A, Gay NJ, Medley GF. 2004 Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol. Infect. 132, 433-441. (doi:10.1017/S0950268804001980)
31. Mossong J et al. 2008 Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 5, e74. (doi:10.1371/journal. pmed.0050074)
32. Wallinga J, Teunis P, Kretzschmar M. 2006 Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am. J. Epidemiol. 164, 936-944. (doi:10.1093/aje/kwj317)
33. Millar EV, O'Brien KL, Watt JP, Bronsdon MA, Dallas J, Whitney CG, Reid R, Santosham M. 2006 Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin. Infect. Dis. 43, 8-15. (doi:10. 1086/504802)
34. Rinta-Kokko H, Dagan R, Givon-Lavi N, Auranen K. 2009 Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 27, 3831-3837. (doi:10.1016/j.vaccine.2009.04.009)
35. Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. 2007 Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 25, 2451-2457. (doi:10.1016/j.vaccine.2006.09.019)
36. Millar EV, O'Brien KL, Zell ER, Bronsdon MA, Reid R, Santosham M. 2009 Nasopharyngeal carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache children before the introduction of pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 28, 711-716. (doi:10.1097/INF.0b013e3181 a06303)
37. Sleeman KL, Griffiths D, Shackley F, Diggle L, Gupta S, Maiden MC, Moxon ER, Crook DW, Peto TEA. 2006 Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J. Infect. Dis. 194, 682-688. (doi:10.1086/505710)
38. Lu Y-J et al. 2008 Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4, e1000159. (doi:10.1371/journal. ppat.1000159)
39. Moffitt KL, Malley R. 2011 Next generation pneumococcal vaccines. Curr. Opin. Immunol. 23, 407-413. (doi:10.1016/j.coi.2011.04.002)
40. Lipsitch M et al. 2012 Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition mode. Epidemiology 23, 1-10. (doi:10.1097/EDE.0b013e31824f2f32)
41. Hoegberg L, Geli P, Ringberg HH, Melander E, Lipsitch M, Ekdahl K, Högberg L. 2007 Age-and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J. Clin. Microbiol. 45, 948-952. (doi:10.1128/JCM.01913-06)
42. Hussain M, Melegaro A, Pebody RG, George R, Edmunds WJ, Talukdar R, Martin SA, Efstratiou A, Miller E. 2005 A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol. Infect. 133, 891-898. (doi:10.1017/S0950268805004012)
43. Spijkerman J, van Gils EJM, Veenhoven RH, Hak E, Yzerman EPF, van der Ende A, Wijmenga-Monsuur AJ, van den Dobbelsteen GPJM, Sanders EAM. 2011 Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg. Infect. Dis. 17, 584-591.
44. Huang SS, Finkelstein JA, Rifas-Shiman SL, Kleinman K, Platt R. 2004 Community-level predictors of pneumococcal carriage and resistance in young children. Am. J. Epidemiol. 159, 645-654. (doi:10.1093/aje/kwh088)
45. Darboe MK, Fulford AJ, Secka O, Prentice AM. 2010 The dynamics of nasopharyngeal Streptococcus pneumoniae carriage among rural Gambian motherinfant pairs. BMC Infect. Dis. 10, 195. (doi:10.1186/ 1471-2334-10-195)
46. Turner P, Hinds J, Turner C, Jankhot A, Gould K, Bentley SD, Nosten F, Goldblatt D. 2011 Improved detection of nasopharyngeal co-colonization by multiple pneumococcal serotypes using latex agglutination or molecular serotyping by microarray. J. Clin. Microbiol. 49, 1784-1789. (doi:10.1128/ JCM.00157-11)
47. Choi YH, Jit M, Gay N, Andrews N, Waight PA, Melegaro A, George R, Miller E. 2011 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS ONE 6, e26190. (doi:10.1371/journal.pone.0026190)
48. Ferguson N, Galvani A, Bush R. 2003 Ecological and immunological determinants of influenza evolution. Nature 422, 428-433. (doi:10.1038/ nature01491.1.)
49. Black S. 2010 The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Pediatr. Infect. Dis. J. 29, 301-303. (doi:10.1097/INF.0b013e3181c391fb)
50. Harboe ZB et al. 2010 Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin. Infect. Dis. 50, 329-337. (doi:10.1086/649872)
51. Lamb KE et al. In press. Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010. Vaccine (doi:10.1016/j.vaccine.2013.05.079)
52. Scott JR et al. 2011 Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in native American communities. J. Infect. Dis. 205, 1-9. (doi:10.1093/ infdis/jir730)
53. Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümke HC, Verbrugh HA, Hermans PWM. 2004 Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 363, 1871-1872. (doi:10.1016/ S0140-6736(04)16357-5)
54. Regev-Yochay G, Lipsitch M, Basset A, Rubinstein E, Dagan R, Raz M, Malley R. 2009 The pneumococcal pilus predicts the absence of Staphylococcus aureus co-colonization in pneumococcal carriers. Clin. Infect. Dis. 48, 760-763. (doi:10.1086/597040)
55. Regev-Yochay G, Dagan R, Raz M, Carmeli Y, Shainberg B, Derazne E, Rahav G, Rubinstein E. 2004 Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. J. Am. Med. Assoc. 292, 716-720. (doi:10.1001/ jama.292.6.716)